Drug intelligence / Profile preview

SP3

Development stage: Preclinical
Lead developer: Serpin Pharma
Modality: Peptides
Administration: Topical

Overview

SP3 is a synthetic peptide developed by Serpin Pharma, derived from the company's platform of serine protease inhibitor (serpin)-based therapeutics. It is specifically designed for skin care applications. Like other candidates in Serpin Pharma's pipeline, SP3 is derived from Alpha-1 Antitrypsin (AAT) and is intended to utilize the protein's natural anti-inflammatory and cytoprotective properties. As of the latest company updates, SP3 has been licensed to a partner for commercial or clinical development in the dermatology and skin care sector.

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on SP3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP3.

Explore the full profile